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vein and PTFE patching.6,8 PTFE patching, however, has
the setback of prolonged hemostasis time.6,9 The
Hemashield patch has been advocated as a means of avoid-
ing this, because the collagen impregnation is believed to
avoid the “needle hole” bleeding seen with PTFE patch
use. It also has the advantage of not requiring pre-clotting
of the graft before implantation, unlike other Dacron
patches. Several studies have shown that collagen-impreg-
nated knitted Dacron is useful in large vessel replacement
procedures.10-12 In an earlier nonrandomized study, we
demonstrated that CEA with Hemashield patching was
associated with increased restenosis and perioperative
stroke rates.13 This study is the first prospective random-
ized trial comparing CEA with PTFE patching versus CEA
with Hemashield patching.
PATIENTS AND METHODS
Between July 1998 and March 2000, 200 CEAs (180
patients) were randomized into 100 CEAs with PTFE
patching (GORE-TEX, W. L. Gore & Associates) and 100
CEAs with collagen-impregnated Dacron patching
(Hemashield, Meadox Medicals). Patients were random-
ized in a 1-to-1 ratio between the two surgical procedures
by using sealed opaque envelopes, each containing a slip of
paper with the procedure assignment. The randomization
Carotid endarterectomy (CEA) is one of the most
commonly performed vascular surgical procedures in the
United States.1 The superiority of CEA has been proven
in several trials that have compared it with medical therapy
alone.2-4 Several authorities have demonstrated more
favorable outcomes in patients treated with patch angio-
plasty than in patients treated with primary closure after
CEA.5-7 Patch angioplasty may be performed with auto-
logous vein or synthetic materials. Two commonly used
synthetic materials are polytetrafluoroethylene (PTFE;
GORE-TEX, W. L. Gore & Associates, Flagstaff, Ariz) or
collagen-impregnated knitted Dacron (Hemashield,
Meadox Medicals, Oakland, NJ [presently Boston
Scientific]). Multiple studies have shown equal results with
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Purpose: Several studies have reported that carotid endarterectomy (CEA) with patch angioplasty has results that are
superior to primary closure. Polytetrafluoroethylene (PTFE) patching has been shown to have results comparable with
autogenous vein patching; however, it requires a prolonged hemostasis time. Therefore, many surgeons are using col-
lagen-impregnated Dacron patching (Hemashield [HP]). This study is the first prospective randomized trial compar-
ing CEA with PTFE patching versus HP patching. 
Methods: Two hundred CEAs were randomized into two groups, 100 PTFE and 100 HP patching. All patients under-
went immediate postoperative and 1-month postoperative color duplex ultrasound scanning studies. Demographic and
clinical characteristics were similar in both groups, including the mean operative diameter of the internal carotid artery.
Results: The perioperative stroke rates were 0% for PTFE, versus 7% for HP (4 major and 3 minor strokes, P = .02).
The combined perioperative stroke and transient ischemic attack rates were 3% for PTFE, versus 12% for HP (P = .047).
The operative mortality rate for PTFE was 0%, versus 2% for HP (P = .477). Five perioperative carotid thromboses
were noted in patients undergoing HP patching, versus none in patients undergoing PTFE patching (P = .07). After 1
month of follow-up, 2% of patients in the PTFE group had a 50% or more restenosis, versus 12% of patients in the HP
group (P = .013). The mean operative time for PTFE patching was 119 minutes, versus 113 minutes for HP patching
(P = .081). The mean hemostasis time was significantly higher for PTFE patching than for HP patching, 14.4 versus
3.4 minutes (P < .001).
Conclusion: CEA with HP patching had a higher incidence of perioperative strokes, carotid thrombosis, and 50% or
more early restenosis than CEA with PTFE patching. However, the mean hemostasis time was higher for PTFE patch-
ing than for HP patching. (J Vasc Surg 2002;35:125-30.)
envelopes were generated in blocks of 10 and placed in a
closed container. After anesthesia was started, but before
the first skin incision, an envelope was pulled from the
container by the study controller and opened, and the sur-
geon was immediately notified of the procedure assign-
ment. Because patients with internal carotid artery
diameters of less than 4 mm were ineligible for the study,
any patient whose intraoperative diameter was less than 4
mm would have been excluded from the study, and the
randomization envelope would have been discarded.
However, there were no patients with internal carotid
artery diameters less than 4 mm.
Patients were excluded from this trial because of these
criteria: repeat CEAs (23 cases), CEAs with concomitant
coronary artery bypass grafting (14 cases), and an internal
carotid artery diameter of less than 4 mm. This study was
approved by the Institutional Review Board of Charleston
Area Medical Center/Robert C. Byrd Health Sciences
Center of West Virginia University.
Before surgery, all patients underwent carotid color
duplex ultrasound scanning, magnetic resonance angiog-
raphy, or both as a means of determining preoperative
stenoses. They also underwent testing for baseline blood
cholesterol and triglyceride levels. Preoperative risk fac-
tors, including hypertension, diabetes mellitus, smoking,
and coronary artery disease were determined for each
patient, along with the preoperative use of antiplatelet
therapy. The indications for surgery were categorized into
hemispheric transient ischemic attacks (TIAs), amaurosis
fugax, hemispheric strokes, nonhemispheric TIAs, and
asymptomatic carotid stenosis.
Operative technique. All CEAs were performed by
using general anesthesia with systemic heparin and routine
shunting with a carotid argyle shunt (C. R. Bard, Billerica,
Mass). No protamine was given at the end of the proce-
dure. At the time of the procedure, the normal internal
carotid artery distal to the lesion was measured in mil-
limeters with calipers. Endarterectomies were extended
proximally and distally beyond grossly diseased intima.
PTFE cardiovascular patches (8 mm wide and 0.4 mm
thick) were used and sutured with PTFE sutures (TT-9
needles, CV-6 sutures). Hemashield patches (8 mm wide)
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Table I. Demographic and clinical data
Hemashield patch PTFE patch Total P value
Sex
Male 55 (55%) 51 (51%) 106 (53%) .671
Female 45 (45%) 49 (49%) 94 (47%)
Mean age (years) 68.5 68.0 .703
Hypertension 74 (74%) 73 (73%) 147 (74%) 1.0
Diabetes mellitus 24 (24%) 34 (34%) 58 (29%) .161
Coronary artery disease 44 (44%) 46 (46%) 90 (45%) .887
Smoking 47 (47%) 49 (49%) 96 (48%) .887
Preoperative cholesterol level (mean) 196 191 .437
Preoperative triglyceride level (mean) 230 222 .728
Preoperative antiplatelet therapy 66 (66%) 65 (65%) 131 (66%) .881
Mean diameter of ICA (mm) 0.58 0.57 .781
Indications for CEA
Hemispheric TIA and/or AF 44 (44%) 42 (42%) 86 (43%) .886
Hemispheric stroke 16 (16%) 8 (8%) 24 (12%) .128
Nonhemispheric TIA 5 (5%) 8 (8%) 13 (7%) .566
Asymptomatic stenosis 35 (35%) 42 (42%) 77 (39%) .383
ICA, Internal carotid artery; CEA, carotid endarterectomy; TIA, transient ischemic attack; AF, amaurosis fugax; PTFE, polytetrafluoroethylene.
Table II. Thirty-day perioperative complications
Hemashield patch PTFE patch P value
Ipsilateral TIA 5 (5%) 3 (3%) .718
Ipsilateral stroke 7 (7%) 0 .02
Combined TIA/stroke 12 (12%) 3 (3%) .047
Perioperative carotid thrombosis 5 (5%) 0 .07
Bleeding 1 (1%) 0 NS
Myocardial infarction 1 (1%) 0 NS
Pneumonia 1 (1%) 0 NS
Death 2 (2%)* 0 NS
Cranial nerve injury 2 (2%)† 2 (2%)‡ NS
*Same two patients who had the myocardial infarction and pneumonia.
†Two hypoglossal nerve injuries (all recovered in 6 months).
‡One hypoglossal nerve and one vagus nerve injury (all recovered within 6 months).
TIA, Transient ischemic attack; PTFE, polytetrafluoroethylene; NS, not significant.
were sutured with 6-0 polypropylene sutures (Prolene,
Ethicon, Somerville, NJ). Thrombin-soaked oxidized cel-
lulose and digital pressure were applied to stop any bleed-
ing points before closure in patients with PTFE patches.
Completion postoperative duplex ultrasound scanning was
performed on all patients. All procedures were drained for
24 hours. Operative and hemostasis times were recorded.
All patients were started on a regimen of aspirin (325 mg
daily) within 24 hours of their surgery.
Surveillance protocol. All patients were examined
postoperatively by a physician who was blinded to the type
of closure, were observed clinically, and underwent imme-
diate postoperative color duplex ultrasound scanning,
which was repeated at 30 days, 6 months, and every 6
months thereafter by using an ATL HDI 3000 system
(Advanced Technology Laboratory, Bellevue, Wash).
Reportable complications were determined in accordance
with the North American Chapter of the International
Society of Cardiovascular Surgery/Society of Vascular
Surgery Ad Hoc Committee Suggested Standards for
Reports Dealing with Cerebrovascular Disease.14 Duplex
scanning was used as a means of assessing the presence of
residual or restenoses. Peak systolic velocities higher than
140 cm/s with spectral broadening throughout systole
and an increased diastolic frequency were consistent with
hemodynamically significant stenoses (≥50% reduction).15
In patients who had duplex findings that were consistent
with tight stenoses (≥70%), the diagnosis was confirmed
with magnetic resonance angiography, conventional arte-
riogram, or carotid exploration (for patients with periop-
erative carotid thrombosis and neurologic deficits).
Statistical methods. Continuous variables (such as
operative time, vessel diameter, and hemostasis time) were
compared for the various surgical closures by using the
Student t test for independent measures. Morbidity rates
and other noncontinuous variables were compared with
either the chi-square test or Fisher exact test. The odds
ratios/relative risks and confidence intervals for primary
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end points (postoperative stroke, carotid occlusion, and
≥50% restenosis) were calculated. Multivariate analyses of
various risk factors were also performed as a means of
determining independent predictors of perioperative
stroke and carotid occlusion. The trial was powered on the
basis of event rates (postoperative stroke, carotid occlu-
sion, and ≥50% restenosis) that were anticipated to occur
in the duration of the trial. For this study to achieve an
80% power of detecting a statistically significant difference
(P = .05) with an expected occurrence of 26% (5% for
strokes and 21% for ≥50% restenosis) for the Hemashield
patch versus 3% (1% for strokes and 2% for ≥50% resteno-
sis) for the PTFE patch, established on the basis of two
previously published studies by our group,5,13 the number
of patients per treatment arm was to have been 88 proce-
dures. The primary analysis of the occurrence of late
events (time to ≥50% restenosis or stroke) will be calcu-
lated with a Kaplan-Meier analysis on completion of the
trial follow-up.
RESULTS
Table I summarizes the demographic and clinical char-
acteristics for both groups. As noted, there were no statis-
tically significant differences between the groups. The
perioperative morbidity and mortality rates are shown in
Table II. Two deaths occurred in the Hemashield group
(one caused by myocardial infarction and one caused by
pneumonia). There were no statistically significant differ-
ences between the groups for bleeding (necessitating re-
exploration or blood transfusion), perioperative myocardial
infarction, or pneumonia.
The perioperative stroke rate was statistically signifi-
cantly higher in patients with Hemashield patching (7%)
than in patients with PTFE patching (0%, P = .02). Of the
seven strokes that occurred in the group with Hemashield
patching, four were major and three were minor. The
combined perioperative stroke and TIA rates were also sta-
tistically significantly higher for patients with Hemashield
Table III. Mean operative and hemostasis time according to type of closure
Hemashield patch PTFE patch P value
Mean operative in minutes (SD) 113 (22) 119 (26) .081
Mean hemostasis time in minutes (SD) 3.4 (3.8) 14.4 (14.5) <.001
PTFE, Polytetrafluoroethylene.
Table IV. Thirty-day postoperative duplex ultrasound scanning results
Hemashield patch PTFE patch P value
≥50% restenosis 7 (7%)* 2 (2%)† .172
Perioperative occlusion 5 (5%) 0 .07
Combined >50% restenosis and 12 (12%) 2 (2%) .013
perioperative occlusion
*Five asymptomatic and two symptomatic (one with TIA and one with a stroke).
†Both asymptomatic.
PTFE, Polytetrafluoroethylene.
patching than for patients with PTFE patching (12% ver-
sus 3%, P = .047). Five perioperative carotid thromboses
were noted in the patients with Hemashield patching ver-
sus none in patients with PTFE patching (P = .07).
There was no difference in the incidence of postoper-
ative TIA/stroke rates in both groups for preoperative
antiplatelet therapy. Five of seven patients (71%) who had
postoperative strokes had preoperative antiplatelet ther-
apy, versus 66% of the whole group (P = .915).
Twenty patients, 16 of whom had PTFE patching on
one side and Hemashield patching on the other side, had
bilateral CEAs. The time between the two CEAs varied
from 1 to 4 months. None of these 16 patients had post-
operative strokes or other complications.
A total of 170 CEAs (90 Hemashield and 80 PTFE)
were performed by one surgeon (A.F.A.), and 30 CEAs
(10 Hemashield and 20 PTFE) were performed by
another surgeon (J.H.K.). The postoperative stroke rates
were comparable for both surgeons: 2.9% (5/170) for the
first surgeon (A.F.A.) versus 6.7% (2/30) for the second
(J.H.K.; P = .628). Similarly, the postoperative stroke rates
in the Hemashield group were also comparable for both
surgeons: 5.6% (5/90) for the first surgeon (A.F.A.) and
20% (2/10) for the second (J.H.K.; P = 1.0).
Overall, five patients with Hemashield patching had
perioperative TIAs; four of these were associated with nor-
mal postoperative duplex ultrasound scans, and one was
associated with a more than 50% restenosis. One of these
patients with TIA symptoms was discovered in the operat-
ing room, and the patient underwent immediate explo-
ration and an intraoperative angiogram, by means of which
a normal CEA was shown. The TIAs in two patients mani-
fested in the recovery room, and both were associated with
normal duplex ultrasound scanning results. The fourth
patient had TIAs 1 week postoperatively and had normal
results on duplex ultrasound scanning. The fifth patient had
a TIA 3 weeks postoperatively and had a more than 50%
restenosis. Perioperative TIAs occurred in three patients
with PTFE patching. Two were noticed in the recovery
room, and both were associated with normal results on
duplex ultrasound scanning. The third patient had a TIA in
the operating room and underwent exploration with intra-
operative angiography, and both were normal. All these
patients were treated with antiplatelet therapy.
Seven patients with Hemashield patching had periop-
erative strokes, five of which were associated with periop-
erative carotid thrombosis, one of which was associated
with a more than 50% stenosis of the internal carotid
artery, and one of which was associated with normal
results on duplex ultrasound scanning. Two of these cases
were discovered in the operating room, four in the recov-
ery room, and one (>50% stenosis) was noticed 4 weeks
postoperatively. Five of these seven patients underwent
immediate exploration with thrombectomy, and the
Hemashield patches were removed and replaced with
PTFE patches. One patient, who had a neurologic deficit
in the operating room, underwent exploration and was
found to have a few platelet aggregates at the site of the
distal suture line that were removed, and the Hemashield
patch was replaced with a PTFE patch. The seventh
patient, who had a more than 50% stenosis (4 weeks post-
operatively) and who was seen several hours after the
stroke, was treated with anticoagulation therapy. Three of
these seven patients had a good recovery (minor strokes),
and four of the patients sustained major strokes.
Table III summarizes the mean hemostasis and opera-
tive times. As noted, the mean operative time for PTFE
patching was 119 minutes, versus 113 minutes for
Hemashield patching (P = .081). The mean hemostasis
time was significantly higher for PTFE patching than
Hemashield patching, 14.4 minutes versus 3.4 minutes (P
< .001).
Table IV illustrates the 30-day postoperative duplex
ultrasound scanning results and type of closure. As noted,
after 1 month of follow-up, 2% of patients who underwent
PTFE patching had a 50% or more restenosis, versus 12%
of patients who underwent Hemashield patching (includ-
ing 5 carotid thromboses, P = .013). No patients in either
group had 50% or more residual stenosis; however, three
patients in the Hemashield group and two patients in the
PTFE group had a less than 50% residual stenosis, and one
patient in each group progressed to a 50% or more steno-
sis. When these two patients are excluded from analysis,
the incidence of 50% or more early restenosis was similar
in both groups, 6% for Hemashield versus 1% for PTFE (P
= .107).
Table V summarizes the odds ratio/relative risks (plus
95% CI) of the postoperative events. It was concluded by
means of multiple linear regression analyses of various risk
factors (age, sex, hypertension, diabetes mellitus, smoking,
coronary artery disease, hypercholesterolemia, preoperative
neurological symptoms, preoperative antiplatelet therapy,
internal carotid artery diameter, type of patch, and surgeon)
that the type of patch was the only independent predictor
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Table V. Odds ratio/relative risk of postoperative events
Hemashield patch PTFE patch Chi-square (P value) Risk ratio (95% CI)
Perioperative stroke 7% 0 5.33 (.021) NA (cannot be calculated)
Perioperative stroke and TIA 12% 3% 4.61 (.032) 4.0 (1.16-13.75)
Any postoperative complication 16% 6% 4.14 (.042) 2.67 (1.09-6.53)
≥50% postoperative restenosis or occlusion 12% 2% 6.22 (.013) 6.0 (1.38-26.12)
≥50% restenosis, occlusion, or death 14% 2% 8.22 (.004) 7.0 (1.63-30.01)
TIA, Transient ischemic attack; PTFE, polytetrafluoroethylene; NA, not applicable.
of postoperative stroke (P = .0042) and early postoperative
50% or more restenosis/occlusion (P = .0056).
DISCUSSION
Several studies have reported that CEA with patch
angioplasty has superior results to primary closure.5-8 The
ideal patch material for CEA has yet to be found, despite
the efforts of many researchers. Both Dacron and PTFE
have been used for carotid angioplasty, and they have the
advantages of availability, resistance to patch rupture and
aneurysmal dilatation, and a reduction in complications
associated with vein harvesting. PTFE patching has been
shown to have results comparable with autogenous vein
patching; however, it requires a prolonged hemostasis
time.6,8 Excessive intraoperative bleeding from needle
holes in the PTFE cardiovascular patches has been
reported.9,16 Other studies have reported no significant
bleeding with the PTFE patches when used during
CEA.17,18 Because of this concern, the use of collagen-
impregnated knitted Dacron patches (Hemashield) has
been advocated in the past several years.
No prospective randomized trial comparing the use of
collagen-impregnated knitted Dacron patches with PTFE
patches or collagen-impregnated knitted Dacron with
plain knitted Dacron in patch angioplasty after CEA was
found by means of a review of the literature.
This study showed that the mean hemostasis time was
significantly higher for PTFE patching than for
Hemashield patching. However, CEA with Hemashield
patching had a higher incidence of perioperative strokes,
carotid thrombosis, and 50% or more early restenosis than
CEA with PTFE patching. The perioperative stroke rates
in the Hemashield group was somewhat higher than what
we anticipated. However, in our previously published
prospective controlled study of CEA with Hemashield
patching (all performed by one surgeon, A.F.A.), the inci-
dence of ipsilateral stroke was 5% (4% perioperatively),
with a combined TIA and stroke rate of 12%.13 The stroke
rates in both studies were similar for the same surgeon
(5.6% vs 4%). Other studies comparing plain Dacron and
vein patching have shown similar results.19,20 Earlier stud-
ies have reported on the usefulness of conventional
Dacron patches in CEAs (ie, non-collagen-impregnated
Dacron patches), with postoperative stroke rates of
approximately 3%.19-22 Archie21 reported on the results of
a nonrandomized series of 1360 CEAs in 15 years; he
compared three types of patches (saphenous vein, PTFE,
Dacron) and concluded that CEAs patched with saphe-
nous veins were superior to CEAs patched with synthetic
materials, particularly Dacron, for stroke and restenosis
rates. Archie also reported the results of a meta-analysis of
three studies that contained both saphenous vein and
Dacron patch reconstruction during CEA and three other
studies that contained both saphenous vein and PTFE
patch reconstruction. The incidence of perioperative
stroke rate for Dacron patching was 3% (598 CEAs) ver-
sus 1% for vein patching (675 CEAs; P = .025). Similarly,
the incidence of perioperative stroke rate for PTFE
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patches was 2.1% (331 CEAs) versus 0.3% for vein patches
(363 CEAs; P = .056).
In a recent study by Ricco et al,23 who analyzed the
use of collagen-impregnated knitted polyester patches
(Hemacarotid patch, Ultrathin, Intervascular) in 221
CEAs, a 1.8% ipsilateral occlusion rate with a 1.4% ipsilat-
eral stroke rate and a 1.4% ipsilateral TIA rate were
reported. They also reported that the percentage of
women free from a more than 50% restenosis was 82% at
3 years, compared with 90% for men for the same period
(P = .035). Because of these results, they felt that the use
of these patches should be restricted to men.
The data presented in this study raise the question of
whether this Hemashield patch is thrombogenic in the
carotid location. There were twice as many patients with
preoperative stroke symptoms in the Hemashield group
than in the PTFE group, which may explain, in part, the
higher postoperative stroke rate in the Hemashield group.
Collagen-impregnated Dacron has gained wide acceptance
as a conduit in aortoiliac reconstruction and aortic
aneurysm repair since the mid-1980s. It has been praised
in the literature for the hemostasis it provides and for its
handling characteristics. Implantation of various grafts in
dogs showed medium-porosity knitted Dacron to have
better endothelial coverage, perigraft attachment, and
thrombus-free surface than collagen-impregnated knitted
Dacron.24 It is possible that the bovine collagen found in
collagen-impregnated knitted Dacron grafts doesn’t expe-
rience the “washout” of collagen in the carotid artery as
fast as it does in a large diameter, high-flow conduit, such
as an aortic graft. Several authors have shown in animal
experimental models that Dacron prostheses have differ-
ent characteristics when placed in the thoracic and abdom-
inal aorta25 and the carotid and femoral sites.26 The
environment of the endarterectomized carotid artery is
very different from that of the aorta, mainly because of the
presence of denuded adventitia with its exposed collagen
along the carotid bifurcation. Studies have shown
increased platelet deposition on both PTFE and knitted
Dacron, with a greater deposition on knitted Dacron.27
In conclusion, CEA with a Hemashield patch has a
higher incidence of perioperative strokes, carotid throm-
bosis, and 50% or more early restenosis than CEA with
PTFE patching. However, the mean hemostasis time is
higher for PTFE patching than for Hemashield patching.
Further long-term follow-up is needed to verify this con-
clusion for restenosis.
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